Zepbound vs Wegovy Cost (2026): Self-Pay, Insurance Copay, Caremark Formulary & Total-Cost Comparison

Zepbound and Wegovy are the two FDA-approved weight-loss-indicated GLP-1 injections in 2026. The cash-pay landscape is closer than it's ever been: Wegovy NovoCare self-pay $299/month standard pen vs Zepbound LillyDirect Self Pay Journey $299/$399/$449/month by strength. With insurance + manufacturer copay savings card both can drop to $25/month. But the CVS Caremark July 2025 formulary swap made Wegovy the preferred step on most commercial Aetna and CVS Caremark formularies — which means the practical insurance cost depends on which formulary you're on. Plus SURMOUNT-5 (NEJM 2025) showed tirzepatide produces ~22% mean weight loss vs ~14% for semaglutide, so the per-pound-lost cost analysis differs from the raw monthly comparison. Below: the head-to-head cost decision.

The short answer

• Cheapest cash-pay Wegovy: $299/month at NovoCare self-pay (standard pen, all doses 0.25-2.4 mg)
• Cheapest cash-pay Zepbound: $299/month at LillyDirect Self Pay Journey Program (2.5 mg vial only). Other vial strengths: $399 (5 mg) or $449 (7.5-15 mg).
• Same price with insurance: as little as $25/month for either drug with manufacturer copay savings card on commercially-insured plans
• BUT: the CVS Caremark July 2025 swap removed Zepbound from most commercial formularies in favor of Wegovy as the preferred step. Patients on a Caremark-managed formulary will likely get Wegovy approved easily and Zepbound denied. Patients on non-Caremark formularies face the inverse.
• Per-pound-lost cost is closer. SURMOUNT-5 (NEJM 2025) showed tirzepatide ~22% weight loss vs semaglutide ~14% — so even at higher per-month cost, Zepbound delivers more weight loss per dollar in the published head-to-head.

Cash-pay side-by-side (verified 2026-05-09)

The CVS Caremark July 2025 formulary swap (the elephant in the room)

On most commercial Aetna and CVS Caremark-managed formularies as of mid-2025, Wegovy is now the single preferred step, and Zepbound requires the Aetna 6981-A P04-2025 Exception process. The affected formulary codes per the verbatim Aetna 6981-A bulletin are ACCF, ACF, ACFC, SCCF, SF, SFC, VF, VFC.

Practical implications for the cost comparison:

• If your plan is on one of those Caremark formulary codes: Wegovy will likely approve cleanly at the standard copay tier ($25/month with savings card). Zepbound requires the 6981-A exception process, which adds delay and is denied for many patients without a documented Wegovy intolerance or failure.
• If your plan is NOT on a Caremark formulary (e.g., some Cigna plans, some BCBS plans): Both drugs typically approve under the same generic GLP-1 weight-management criteria.
• Cash-pay path is unaffected by formulary. NovoCare self-pay $299/month Wegovy and LillyDirect $299-$449/month Zepbound are available regardless of insurance. If you can't get Zepbound through insurance, the LillyDirect path is the workaround.

For the full Aetna PA criteria including 6981-A and 6947-C, see our Aetna PA guide. For the Cigna IP0206 weight-management criteria (no Caremark-style preferred-step swap), see our Cigna PA guide.

Per-pound-lost cost analysis

Raw monthly cost comparison favors Wegovy ($299) over Zepbound ($299-$449) at LillyDirect rates. But the SURMOUNT-5 (NEJM 2025) head-to-head showed tirzepatide produces materially more weight loss than semaglutide. If your goal is weight loss per dollar, the math changes:

Caveats on the per-pound math:

• The cost-per-pound calculations assume sustained therapy for 18 months — most weight loss happens in the first year, with maintenance dosing thereafter
• Trial weight loss is a population mean; individual response varies
• Discontinuation produces ~2/3 regain at 1 year per the STEP-1 extension (Diabetes Obes Metab 2022, PMID 35315183) — which means the “cost-per-pound” is really the cost-per-pound-while-you-keep-taking-it. See our Life After GLP-1 maintenance hub for the long-term maintenance considerations.
• Insurance-covered access at $25/month copay makes both drugs nearly equivalent in cost — the choice then comes down to formulary access, side-effect tolerance, and efficacy preference rather than dollars

HSA / FSA eligibility

Brand-name Wegovy and Zepbound are generally HSA/FSA eligible as a medical expense with a valid prescription per IRS Publication 502. This applies to NovoCare and LillyDirect cash-pay purchases as well as insurance-copay payments. The manufacturer copay savings cards CAN sometimes be combined with HSA/FSA payment — verify with your plan administrator. Compounded semaglutide / tirzepatide from licensed 503A pharmacies are typically also HSA/FSA eligible with a prescription, though some plan administrators require a Letter of Medical Necessity.

Decision framework: which costs less for you?

• You have commercial insurance with both drugs on formulary, no Caremark preferred-step issue: Either is $25/month with copay savings card. Choose based on efficacy preference (Zepbound) or familiarity with semaglutide (Wegovy).
• You have commercial insurance on a CVS Caremark-managed formulary with the 6981-A exception codes: Wegovy will approve easily; Zepbound requires exception process. Default to Wegovy unless you have a documented intolerance.
• You're cash-pay and want the cheapest monthly: NovoCare $299/month Wegovy standard pen OR LillyDirect $299/month Zepbound 2.5 mg vial (the starting dose). Wegovy if you want to escalate without dose-tier price changes.
• You're cash-pay and want maximum weight loss for the dollar: Zepbound at LillyDirect $449/month (7.5-15 mg vials) — costs ~50% more per month than NovoCare Wegovy but delivers ~40% more weight loss per the SURMOUNT-5 head-to-head.
• You want the cheapest brand-name oral option: Wegovy oral pill 1.5/4 mg at NovoCare $149/month OR Foundayo (orforglipron, oral GLP-1) at $149/month — both are oral, both are $149/mo. Foundayo is a different molecule (not semaglutide).
• You're Medicare-eligible: Wegovy and Zepbound (KwikPen only) become available on Medicare Part D Bridge starting 07/01/2026 at $50/month flat copay for eligible MA-PD members (BMI ≥27 + heart disease or prediabetes). Bridge runs through 12/31/2027.